GO2 Foundation for Lung Cancer played a vital role in establishing the Lung Cancer Research Program (LCRP) within the Congressionally Directed Medical Research Program administered by the Department of Defense. The LCRP is the largest lung cancer research program – public or private – outside of the National Cancer Institute at the National Institutes of Health. Every year, we work with our chairs at the Congressional Lung Cancer Caucus and the lung cancer community to increase funding to the original appropriation of $20 million.

The LCRP actively conducts clinical trials testing new therapies, including immunotherapies and novel types of precision medicines for patients with specific genetic changes in their lung cancer. To continue addressing gaps in research, we ask that Congress fund the LCRP at the original $20 million.

Lung Cancer Is The Leading Cause of Cancer Death

$155.5 Million
Total Appropriations for the LCRP from FY09-FY20

Risk Assessment
Prevention
Early Detection
Treatment
Survivorship & Outcome
A Call to Action

Lung cancer kills more people than any other cancer, but still receives less funding. The Lung Cancer Research Program (LCRP) within the Congressionally Directed Medical Research Program administered by the Department of Defense was established in 2008 with $20 million in FY 2009 federal appropriations. It has played a critical role in supporting high-impact, innovative lung cancer research within the military and general public. Congress must support this research at the appropriated level of $20 million!

Why Fund a Lung Cancer Research Program?

VISION
Eradicate deaths from lung cancer to better the health and welfare of the military and the American public.

MISSION
Support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, and treatment for the control and cure of lung cancer.

A Critical Need for Lung Cancer Research

• Lung cancer is the leading cause of cancer deaths in the U.S.
• The 5-year survival rate is only 21% despite advancements in lung cancer treatments.
• Research grants have been limited because LCRP has been underfunded the past 11 years below its original $20M level.
• Lung cancer is underfunded and underrepresented relative to its high rates of mortality.